ACADIA PHARMACEUTICALS INC (ACAD)

US0042251084 - Common Stock

24.85  -0.02 (-0.08%)

After market: 24.82 -0.03 (-0.12%)

News Image
14 days ago - InvestorPlace

The 3 Most Undervalued Biotech Stocks to Buy in February 2024

With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.

News Image
14 days ago - BusinessInsider

The 3 Most Undervalued Biotech Stocks to Buy in February 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With patience, some of the most undervalued biotech stocks can create massive w...

News Image
23 days ago - Acadia Pharmaceuticals Inc.

Acadia Announces Additions to Executive Team

News Image
23 days ago - Seeking Alpha

Baird starts Acadia at outperform ahead of Phase 3 data (NASDAQ:ACAD)

Baird has initiated coverage of Acadia (ACAD) at outperform, citing favorable risk/reward ahead of Phase 3 data for Nuplazid in the treatment of schizophrenia. Read more here.

News Image
a month ago - Seeking Alpha

Needham upgrades Acadia to buy, cites physician support for Daybue (NASDAQ:ACAD)

Needham upgrades Acadia Pharmaceuticals (ACAD) to buy, citing potential upside to Daybue sales and upcoming data for its schizophrenia drug candidate. Read more here.

News Image
2 months ago - Market News Video

ACAD December 2025 Options Begin Trading

News Image
2 months ago - Seeking Alpha

Acadia Pharma stock ticks lower amid Deutsche Bank downgrade after surge on patent win

Acadia Pharmaceuticals (ACAD) fell 1.6% after Deutsche Bank downgraded the stock following a patent win for its Parkinson's treatment, Nuplazid.

News Image
2 months ago - Investor's Business Daily

Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug

MSN Labs lost out in a summary judgement to knock off Acadia's Nuplazid.

News Image
2 months ago - Market News Video

Notable Wednesday Option Activity: BA, ACAD, DLR

News Image
2 months ago - Seeking Alpha

Acadia Pharmaceuticals stock surges 32% after win in patent suit over Nuplazid

Acadia Pharmaceuticals (ACAD) surges 28% after winning a patent suit regarding its Parkinsons disease drug Nuplazid.

News Image
3 months ago - Seeking Alpha

Acadia starts Phase 3 study for Prader-Willi hunger treatment (ACAD)

Acadia Pharmaceuticals (ACAD) had initiated a Phase 3 study for carbetocin nasal spray to treat hyperphagia in Prader-Willi syndrome patients. Read more here.

News Image
4 months ago - InvestorPlace

3 Biotech Stocks With the Strongest Clinical Pipelines

Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.

News Image
4 months ago - Seeking Alpha

Acadia Pharma GAAP EPS of -$0.40 beats by $0.05, revenue of $211.7M beats by $22.08M (NASDAQ:ACAD)

Acadia Pharma beats earnings expectations with record revenues from DAYBUE and NUPLAZID, and provides positive outlook for 2023.